NCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT05495464 2026-02-27
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04855695 2026-01-21
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
NCT07052695 2025-12-15
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05951959 2025-10-21
TrAVeRse
AstraZeneca
Phase 2 Active not recruiting
NCT06520098 2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2 Recruiting
NCT04546620 2025-08-06
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Phase 2 Active not recruiting
NCT04662255 2025-05-28
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02112526 2024-12-20
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 1 Completed
NCT04961801 2022-03-08
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Withdrawn